Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CGEN Compugen Ltd

-0.012 (-1.79%)
Last Updated: 11:40:36
Delayed by 15 minutes


Draw Mode:

Volume 42,692
Bid Price 0.656
Ask Price 0.6672
News -
Day High 0.666399


52 Week Range


Day Low 0.6527
Company Name Stock Ticker Symbol Market Type
Compugen Ltd CGEN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.012 -1.79% 0.657 11:40:36
Open Price Low Price High Price Close Price Prev Close
0.66 0.6527 0.666399 0.669
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
96 42,692 $ 0.6584708 $ 28,111 - 0.53 - 1.4897
Last Trade Time Type Quantity Stock Price Currency
11:39:30 100 $ 0.657 USD

Compugen Ltd Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
58.23M 88.23M - 7.5M -33.69M -0.38 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Compugen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No CGEN Message Board. Create One! See More Posts on CGEN Message Board See More Message Board Posts

Historical CGEN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.640.6780.620.6523553150,0260.0172.66%
1 Month0.78420.79050.530.6320724236,624-0.1272-16.22%
3 Months1.051.110.530.7727692169,688-0.393-37.43%
6 Months1.081.48970.531.08306,902-0.423-39.17%
1 Year1.011.48970.530.9479091395,656-0.353-34.95%
3 Years13.0615.160.515.02854,606-12.40-94.97%
5 Years3.4119.900.517.56777,506-2.75-80.73%

Compugen Description

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Your Recent History